ESCITALOPRAM MARKET

INTRODUCTION ESCITALOPRAM MARKET

Escitalopram is used to treat anxiety disorders and depression. (GAD). It is an antidepressant that is categorised as a selective serotonin reuptake inhibitor, a class of drugs. (SSRIs).

The serotonin chemical's activity in the brain is increased by these medications.The results of appropriate studies conducted to yet have not revealed geriatric-specific issues that would restrict escitalopram's efficacy in the elderly.

However, elderly people are more prone to have age-related liver issues and hyponatremia (low salt in the blood), which may necessitate caution and a dose adjustment for those using escitalopram.

Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class and is marketed under the brand names Lexapro and Cipralex, among others.Major depressive disorder and generalised anxiety disorder are the two conditions escitalopram is typically used to treat.It is only accessible commercially as an oxalate salt and is taken orally.

Typical adverse reactions include fatigue, nausea, and issues with sexual function.Escitalopram has FDA approval for the treatment of generalised anxiety disorder in adults as well as major depressive disorder in adolescents and adults.

Escitalopram is one of the most efficient and well-tolerated antidepressants for treating major depressive disorder in adults for a short period of time (acutely).The one that is safest to give to kids and teenagers is this one.

ESCITALOPRAM MARKET SIZE AND FORECAST

The Global EscitalopramMarket accountedfor $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

ESCITALOPRAM MARKET RECENT DEVELOPMENT

Escitalopram, a popular selective serotonin reuptake inhibitor (SSRI) for the treatment of depression, is the S-enantiomer of the racemic drug citalopram. This review outlines the pharmacological and clinical data that are now available to support the use of escitalopram as a therapy for depression and anxiety.

  Escitalopram, 10 mg/day, has a great safety and tolerability profile and has been shown in clinical trials to be as efficacious as citalopram, the chemical that it is derived from. Escitalopram represents a development in SSRI therapy for symptoms of anxiety and depression because of its improved selectivity. 

The most frequent side-effect, especially in older persons, is weariness or somnolence, while patients who already have daytime sleepiness and fatigue may paradoxically see an improvement in these symptoms. Escitalopram's effects on serial response time, logical thinking, serial subtraction, multitasking, or Mackworth Clock task performance have not been demonstrated.

ESCITALOPRAM MARKET COMPANY PROFILE

• Alivate-E
• Censpram Plus
• Articalm
• Alwel
• Zuventus

THIS ESCITALOPRAM MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many Escitalopram are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Escitalopram And key vendor selection criteria
3. Where is Escitalopram Manufactured? What is the average margin per unit?
4. Market share of Global Escitalopram Market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Escitalopram In-house
6. key predictions for next 5 years in Global Escitalopram Market
7. Average B-2-B Escitalopram Market price in all segments
8. Latest trends in Escitalopram Market, by every market segment
9. The market size (both volume and value) of the Escitalopram Market in 2024-2030 and every year in between?
10. Production breakup of Escitalopram Market, by suppliers and their OEM relationship